Table 7 Selected pathways identified in DAVID for differentially expressed target genes (DET) and their corresponding miRNAs
No. | Pathway | Pathway P value | Number of genes | Gene name | Fold change | FDR | DET-related identified miRNA |
|---|---|---|---|---|---|---|---|
1 | RIG-I-like receptor signalling pathway | 5.2E−04 | 8 | ddx3x | 1.59 ↑ | 1.15E−2 | miR-101 ↑, miR-1↓, miR-133a/b↓, miR-208↓ |
traf3 | 1.31 ↑ | 1.11E−2 | miR-30↓, miR-155↑, miR-133a/b↓ | ||||
cxcl10 | 56.62 ↑ | 2.16E−5 | miR-142-3p↓ | ||||
cyld | 1.78 ↑ | 1.19E−3 | miR-30↓, miR-133a/b↓ | ||||
ikbke | 2.27 ↑ | 2.44E−3 | miR-155↑, miR-128↓ | ||||
mapk14 | 1.68 ↑ | 5.43E−3 | miR-128↓, miR-101↑ | ||||
map3k7 | − 1.58 ↓ | 4.02E−3 | miR-30↓, miR-101↑, miR-155↑, miR-204↑ | ||||
rnf125 | 1.88 ↑ | 9.59E−3 | miR-101↑, miR-142-3p↓ | ||||
2 | Hyper-trophy cardiomyopathy | 1.5E−03 | 8 | cacnb1 | − 1.42 ↓ | 1.10E−3 | miR-204↑, miR-208↓ |
dag1 | − 1.91 ↓ | 4.43E−3 | miR-142-3p↓, miR-101↑, miR-30↓ | ||||
itga2 | − 1.32 ↓ | 7.08E−3 | miR-30↓, miR-101↑, miR-128↓ | ||||
itgav | − 1.49 ↓ | 6.71E−3 | miR-142-3p↓ | ||||
prkaa2 | − 1.69 ↓ | 5.03E−3 | miR-30↓, miR-146a/b↑ | ||||
sgcd | 1.33 ↑ | 1.34E−3 | miR-142-3p↓ | ||||
tpm1 | − 1.85 ↓ | 2.02E−4 | miR-142-3p↓, miR-542↓ | ||||
tpm3 | − 2.87 ↓ | 1.08E−2 | miR-204↑, miR-221/222↑ | ||||
3 | MAPK signalling pathway | 7.3E−03 | 13 | bdnf | − 2.08 ↓ | 9.14E−4 | miR-1↓, miR-206↓, miR-155↑, miR-30↓, miR-204↑ |
cacnb1 | − 1.42 ↓ | 1.10E−3 | miR-204↑, miR-208↓ | ||||
dusp1 | 1.77 ↑ | 2.80E−3 | miR-133a/b↓, miR-101↑ | ||||
mecom | 1.50 ↑ | 1.34E−3 | miR-1↓, miR-133a/b↓, miR-206↓, miR-142-3p↓ | ||||
fgf11 | − 1.36 ↓ | 1.11E−2 | miR-331↓ | ||||
fgf7 | 5.83 ↑ | 2.33E−3 | miR-101↑, miR-155↑, miR-142-3p↓ | ||||
mapk14 | 1.68 ↑ | 5.43E−3 | miR-128↓, miR-101↑ | ||||
map3k7 | − 1.58 ↓ | 4.02E−3 | miR-30↓, miR-101↑, miR-155↑, miR-204↑ | ||||
map3k4 | − 1.36 ↓ | 9.06E−3 | miR-101↑, miR-128↓ | ||||
ntf3 | 1.72 ↑ | 2.44E−3 | miR-221/222↑ | ||||
pla2g4a | 2.27 ↑ | 1.39E−3 | miR-142-3p↓ | ||||
dgfra | 2.82 ↑ | 1.47E−3 | miR-142-3p↓ | ||||
sos2 | − 1.62 ↓ | 9.09E−3 | miR-208↓, miR-204↑, miR-221/222↑ | ||||
4 | p38 MAPK | 9.9E−02 | 4 | mapk14 | 1.68 ↑ | 5.43E−3 | miR-128↓, miR-101↑ |
map3k4 | − 1.36 ↓ | 9.01E−3 | miR-101↑, miR-128↓ | ||||
map3k7 | −1.58 ↓ | 4.02E−3 | miR-30↓, miR-101↑, miR-155↑, miR-204↑ | ||||
dusp1 | 1.77 ↑ | 2.80E−3 | miR-133a/b↓, miR-101↑ | ||||
5 | Toll-like receptor signalling pathway | 1.6E−02 | 7 | traf3 | 1.31 ↑ | 1.11E−2 | miR-30↓, miR-155↑, miR-133a/b↓ |
cxcl10 | 56.62 ↑ | 2.16E−5 | miR-142-3p↓ | ||||
cxcl11 | 14.20 ↑ | 9.51E−5 | miR-1↓, miR-206↓ | ||||
tlr4 | 1.44 ↑ | 9.52E−4 | miR-542↓, miR-374↑ | ||||
ikbke | 2.27 ↑ | 2.44E−3 | miR-155↑, miR-128↓ | ||||
mapk14 | 1.68 ↑ | 5.43E−3 | miR-128↓, miR-101↑ | ||||
map3k7 | − 1.58 ↓ | 4.02E−3 | miR-30↓, miR-101↑, miR-155↑, miR-204↑ | ||||
6 | Ubiquitin-mediated proteolysis | 2.0E−02 | 8 | rhobtb2 | − 1.62 ↓ | 9.15E−3 | miR-204↑, miR-133↓ |
cul3 | − 1.71 ↓ | 4.76E−5 | miR-101↑, miR-193a↑ | ||||
cul4b | 1.58 ↑ | 1.08E−3 | miR-133a/b↓, miR-101↑ | ||||
mid1 | − 1.40 ↓ | 1.01E−2 | miR-374↓, miR-542-3p↓ | ||||
nedd4 | − 1.30 ↓ | 1.00E−2 | miR-30↓, miR-128↓ | ||||
trim32 | 1.50 ↑ | 1.13E−2 | miR-155↑, miR-142-3p↓ | ||||
ube2g1 | − 1.41 ↓ | 5.46E−4 | miR-101↑, miR-30↓, | ||||
ube2h | − 1.53 ↓ | 3.80E−3 | miR-1↓, miR-206↓, miR-204↑, miR-101↑ | ||||
7 | Ras pathway | 3.4E−02 | 6 | tiam2 | − 1.44 ↓ | 3.27E−3 | miR-101↑ |
sos2 | − 1.54 ↓ | 9.09E−3 | miR-193↑, miR-208↓, | ||||
ets1 | 1.98 ↑ | 7.19E−3 | miR-193↑, miR-208↑, miR-101↑, miR-221/222↑, miR-1↓, miR-206↓ | ||||
mapk14 | 1.68 ↑ | 5.43E−3 | miR-128↓, miR-101↑ | ||||
map3k7 | − 1.58 ↓ | 4.02E−3 | miR-30↓, miR-101↑, miR-155↑, miR-204↑ | ||||
map3k4 | − 1.36 ↓ | 9.01E3 | miR-101↑, miR-128↓ | ||||
8 | Oxidative stress response | 3.9E−02 | 5 | dusp1 | 1.77 ↑ | 2.80E−3 | miR-133a/b↓, miR-101↑ |
dusp19 | − 1.55 ↓ | 2.09E−3 | miR-204↑ | ||||
mapk14 | 1.68 ↑ | 5.43E−3 | miR-128↓, miR-101↑ | ||||
map3k4 | − 1.36 ↓ | 9.01E−3 | miR-101↑, miR-128↓ | ||||
pla2g4a | 2.27 ↑ | 1.39E−3 | miR-142-3p↓ |